Recruiting
Familial dilated cardiomyopathy
RecruitingStudy of ALXN2350 gene therapy in adults with BAG3 mutation-associated dilated cardiomyopathy: A safety and efficacy trial
Registered drugNo placebo
Study of ALXN2350 gene therapy in adults with BAG3 mutation-associated dilated cardiomyopathy: A safety and efficacy trial
Registered drugNo placebo
- Disease:Familial dilated cardiomyopathy
- Substances:AAV9-CTNT-COBAG3Prednisone+3
Countries:
Germany
Germany- Participants:18–64 years · 65+ years
- Substances:AAV9-CTNT-COBAG3
- Sponsor:Alexion Pharmaceuticals Inc.


